Top Tweets for #Imdevimab
#HAS 2021,
autorisation avant l'autorisation... d'anticorps monoclonaux contre Covid.
#Caserivimab
#Imdevimab
Pas de chance,
1) interactions avec les "vaccins" :
https://t.co/1JBBum8PFX
2) proscrit en cas d'infection par #Omicron
https://t.co/9OocRLAMeE
https://t.co/FfVFcDPrhm
#Communiqué | #COVID19 - La HAS accorde une autorisation d’accès précoce pré-AMM au traitement Ronapreve® en prophylaxie chez certains patients immunodéprimés à très haut risque de forme sévère de Covid-19
👉 https://t.co/yHRMs7ObyX
Les avis 👉 https://t.co/tyKXt2PpRV
Según estos datos de @NEJM #remdesivir, #molnupiravir, #nirmatrelvir así como mABs como #bebtelovimab o #imdevimab mantendrían cierta actividad IN VITRO para BA.4.64
https://t.co/wBoGVuzBrL
„Erstmals ist ein neuer COVID-Wirkstoff noch während der Nutzenbewertung des G-BA von einer veränderten Virusvariante überholt worden.“ - Sagt das jetzt mehr über das Virus, oder mehr über das dt. Gesundheitswesen, frag ich mich 🤔
#Casirivimab #Imdevimab https://t.co/8KGiSnMmXy
"The virus has since evolved, and mounting evidence from lab tests suggests the two therapies - #sotrovimab as well as #casirivimab-#imdevimab - have limited clinical activity against the latest iterations of the virus."
#SARSCoV2 #therapeutics
https://t.co/Qebk4LHKDD
Ισχυρή σύσταση του @WHO ενάντια σε δύο θεραπείες με #αντισώματα κατά της #Covid19, τις οποίες θεωρεί πλέον αναποτελεσματικές
https://t.co/cLTFoIHB6O
#sotrovimab #casirivimab-#imdevimab
The #SatoLab @SystemsVirology has the effect of 10 therapeutic monoc. #Antibodies against #BA275 evaluated (preprint):
#Adintrevimab
#bamlanivimab
#casirivimab
#etesevimab
#imdevimab didn't work
#Regdanvimab
#sotrovimab
#tixagevimab were functional against #Centaurus
The #Sato Lab @SystemsVirology hat die Wirkung von 10 therapeutischen monok. Antikörpern gegen #BA275 bewertet (Preprint):
#Adintrevimab
#bamlanivimab
#casirivimab
#etesevimab
#imdevimab wirkten nicht
#Regdanvimab
#sotrovimab
#tixagevimab waren gegen #Centaurus funktionsfähig
Excellent data!
#Adintrevimab, #bamlanivimab, #casirivimab, #etesevimab, and #imdevimab did not work against BA.2.75
#Regdanvimab, #sotrovimab, and #tixagevimab were functional against BA.2.75
1⃣ BA.2, BA.4/5と同様に、BA.2.75は、#adintrevimab, #bamlanivimab, #casirivimab, #etesevimab, #imdevimab に抵抗性を示しました（全然効かない）。7/11
1⃣ #adintrevimab, #bamlanivimab, #casirivimab, #etesevimab & #imdevimab did not work against all Omicron subvariants tested including BA.2, BA.4/5 and BA.2.75. 7/11
New in @TheLancetInfDis> Efficacy and safety of a single dose of #casirivimab and #imdevimab for the prevention of #COVID19 over an 8-month period: a randomised, double-blind, placebo-controlled trial https://t.co/WiPIdLc0uW
May #casirivimab/#Imdevimab treatment for COVID-19 infection improve #axial #symptoms in advanced #PD? Out now in #CJNS our recent clinical observation. @CNSFNeuroLinks @Ausl_RE #IRCCS_RE
https://t.co/E2oFlQQepp
Casirivimab/imdevimab improve outcomes in early COVID-19 https://t.co/d5Fcjx3ep6 #Coronavirus #Disease #COVID #Monoclonal #Antibody #Casirivimab #Imdevimab @VirusesMDPI @univ_toyama
#bamlanivimab, #casirivimab, #etesevimab, #imdevimab and #tixagevimab did not work against new Omicron subvariants (w/ Spike L452 mutations which includes BA.2.11, BA.2.12.1, BA.4 and BA.5)
#ECCMID2022 @Airfinity #bamlanvimab #etesivimab #casirivimab #imdevimab please reach out to @Airfinity if you want to evaluate this treatment in a global context
Study found treatment with subcutaneous #casirivimab and #imdevimab antibody combination compared with placebo significantly reduced the incidence of symptomatic #COVID19 among recently exposed, asymptomatic individuals. https://t.co/7Mk6V2ZMQc
Therapies for Nonhospitalized COVID-19 Patients, update 19th Jan 2022.
#bamlanivimab+#etesevimab, #casirivimab+#imdevimab, #sotrovimab #Omicron, #remdesivir #Paxlovid #molnupiravir
https://t.co/4hFm0W7rCj
#treatment with subcutaneous #casirivimab and #imdevimab antibody combination compared with placebo significantly reduced the incidence of symptomatic #COVID19 among recently exposed, asymptomatic individuals. @JAMA_current
#SARS_CoV_2 @isciverse
https://t.co/5fuiaVtz7l
Study found treatment with subcutaneous #casirivimab and #imdevimab antibody combination compared with placebo significantly reduced the incidence of symptomatic #COVID19 among recently exposed, asymptomatic individuals. https://t.co/USHxSRjsI5
Study found treatment with subcutaneous #casirivimab and #imdevimab antibody combination compared with placebo significantly reduced the incidence of symptomatic #COVID19 among recently exposed, asymptomatic individuals. https://t.co/T7GuYt8gv8
Last Seen Hashtags on Sotwe
Trends for you
Most Popular Users
Elon Musk 
@elonmusk
240.4M followers
Barack Obama
@barackobama
119.3M followers
Donald J. Trump
@realdonaldtrump
111.7M followers
Cristiano Ronaldo
@cristiano
110M followers
Narendra Modi
@narendramodi
107M followers
Rihanna
@rihanna
97.5M followers
NASA
@nasa
92.1M followers
Justin Bieber
@justinbieber
90.8M followers
KATY PERRY
@katyperry
87.3M followers
Taylor Swift
@taylorswift13
81.2M followers
Lady Gaga
@ladygaga
72.7M followers
Kim Kardashian
@kimkardashian
69.6M followers
Virat Kohli
@imvkohli
69.4M followers
YouTube
@youtube
68.6M followers
Bill Gates
@billgates
63.7M followers
The Ellen Show
@theellenshow
62.5M followers
Neymar Jr
@neymarjr
62.1M followers
CNN
@cnn
61.9M followers
X
@x
60.9M followers
Selena Gomez
@selenagomez
60.4M followers